PBA
VERA icon

Paradigm Biocapital Advisors’s Vera Therapeutics VERA Stock Holding History

Paradigm Biocapital Advisors’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,437,339
Closed -$60.8M – 32
2024
Q4 		$60.8M Buy
1,437,339
+340,488
+31% +$15.1M 2.11% 14
2024
Q3 		$48.5M Buy
+1,096,851
New +$41.6M 1.64% 19

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Paradigm Biocapital Advisors's VERA Position: Q1 2025 in Review

Paradigm Biocapital Advisors sold out of Vera Therapeutics (VERA) in Q1 2025, closing a stake of 1,437,339 shares — an estimated $60.8M sold.

Paradigm Biocapital Advisors first reported a position in VERA in Q3 2024 and held it in 2 quarters. The position peaked at $60.8M in Q4 2024. 179 funds tracked by Wall St. Rank hold VERA as of Q1 2025.

  • Paradigm Biocapital Advisors reported no remaining Vera Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,437,339 Vera Therapeutics shares in Q1 2025, an estimated $60.8M.
  • Paradigm Biocapital Advisors first reported a position in Vera Therapeutics in Q3 2024 and held it in 2 quarters.
  • Paradigm Biocapital Advisors's Vera Therapeutics position peaked at $60.8M in Q4 2024.
  • 179 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2025, filed 15 May 2025.